Dossier assessment

Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A19-41
Last updated

Report documents

  1. Extract of dossier assessment

    Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 661 kB, EN, not accessible
  2. Dossier assessment

    Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible

Dossier assessment

Indication:

Adults with moderate to severe plaque psoriasis

Result of dossier assessment:

Proof of considerable added benefit for patients with inadequate response or intolerance to systemic therapy. Due to a lack of relevant study data, an added benefit is not proven for patients who are not candidates for conventional therapy in the framework of a first systemic therapy.

Additional information

Federal Joint Committee (G-BA)

2019-11-22 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A19-41
Commission
Commission awarded on 03.05.2019 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Addendum

    Risankizumab (plaque psoriasis) - Addendum to Commission A19-41

    Project no.
    A19-87
    Last updated

    Status: Commission completed

  2. Addendum

    Risankizumab (plaque psoriasis) - Second Addendum to Commission A19-41

    Project no.
    G19-16
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Risankizumab (plaque psoriasis in children and adolescents) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A26-93
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Risankizumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-84
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V

    Project no.
    A22-133
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-156
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form